bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 5 from Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
Authors: Chen Jun , Kinoshita Taisei , Sukbuntherng Juthamas , Chang Betty Y. , Elias Laurence
Published: April 2023

Supplementary Figure S5. Ibrutinib irreversibly inhibited SK-BR-3 cells, and bound covalently to EGFR and HER4 in rapid dilution assays. (A) SK-BR-3 cells were treated with ibrutinib at 0.1 and 0.5 ÂµM for varied times before washing twice with fresh media or media with drug, as for no-washout group. Cells were cultured for another 2 hours after washout before harvesting. (B) The growth of SK-BR-3 cells was still inhibited 6 days after original treatment with ibrutinib for 1 hour using wash-out step. Cells were plated in 10 cm plate in triplicate, and washout was repeated twice. The cells were counted with Coulter counter. *P<0.05, compared with control. Potency of irreversible binding to EGFR (C) and HER4 (D) by ibrutinib, afatinib, and neratinib with rapid dilution assays. The value of kobs quantifies the potency of covalent bond formation. BTK was assayed as a comparison (C). The labeled time indicates pre-incubation time for test compound and enzyme.
Supplementary Figure 2 from Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
Authors: Chen Jun , Kinoshita Taisei , Sukbuntherng Juthamas , Chang Betty Y. , Elias Laurence
Published: April 2023

Supplementary Figure S2. Response of BT-474 (A) and SK-BR-3 (B) cells to treatment with different ErbB kinase inhibitors. The cells were treated with inhibitors continuously for 72 hours, and alamarBlueÂ® assay was used to quantify cell growth.
Supplemental Figures 1 to 9 from Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R
Authors: de Lint Klaas , Poell Jos B. , Soueidan Hayssam , Jastrzebski Katarzyna , Vidal Rodriguez Jordi , Lieftink Cor , Wessels Lodewyk F.A. , Beijersbergen Roderick L.
Published: April 2023

Supplementary Figure 1 | IGF1R inhibition by NVP-AEW541 increases sensitivity to PI3K inhibition by GDC-0941 in HCC1806 and CAL-51 cells Supplementary Figure 2 | GDC-0941 dose-response curves of the TNBC cell line panel at different concentrations of OSI-906 Supplementary Figure 3 | IGF1R, pIGF1R and IGF2BP3 levels in the 18 cell lines of the panel Supplementary Figure 4 | Sensitivity of the TNBC cell line panel to MEK-inhibitor PD-0325901 Supplementary Figure 5 | Dynamic quantification of apoptosis in CAL-51 cells after drug exposure Supplementary Figure 6 | HCC1806 cells become resistant to GDC-0941 after prolonged exposure but are still sensitive to combination treatment Supplementary Figure 7 | Overexpression of IGF1R has no significant effect on sensitivity to GDC-0941 in HCC1806, CAL-51, CAL-148 and MFM-223 cells Supplementary Figure 8 | Colony outgrowth of wild type and IGF1R-overexpressing cell lines Supplementary Figure 9 | Antibodies raised against IGF2 do not modulate the response of CAL-148 and MFM-223 cells to GDC-0941
Supplementary Table S1; Supplementary Fig. S1-S4 from FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors
Authors: Tong Jingshan , Tan Shuai , Nikolovska-Coleska Zaneta , Yu Jian , Zou Fangdong , Zhang Lin
Published: April 2023

Supplementary Table S1 shows 17-AAG IC50 in 6 CRC cell lines with different KRAS, BRAF, PIK3CA, p53 and FBW7 genotypes. Supplementary Fig. S1 shows induction of proapoptotic Bcl-2 family proteins by 17-AAG in FBW7-mutant colon cancer cells. Supplementary Fig. S2 shows that FBW7 is critical for cell death and Mcl-1 degradation induced by Hsp90 inhibitors in DLD1 and SW48 cells. Supplementary Fig. S3 shows that Mcl-1 depletion induced by Hsp90 inhibitors is mediated by protein degradation, but not decreased mRNA expression. Supplementary Fig S4 shows that necroptosis and autophagy induced by 5-fluorouracil is not affected in Mcl-1-KI cells.
Supplemental Figure legend from Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations
Authors: Gebreyohannes Yemarshet K. , Schöffski Patrick , Van Looy Thomas , Wellens Jasmien , Vreys Lise , Cornillie Jasmien , Vanleeuw Ulla , Aftab Dana T. , Debiec-Rychter Maria , Sciot Raf , Wozniak Agnieszka
Published: April 2023

Representative images of H&E, KIT and DOG1 staining performed in the xenograft models
Figure S4 from Combined PPARγ Activation and XIAP Inhibition as a Potential Therapeutic Strategy for Ovarian Granulosa Cell Tumors
Authors: Leung Dilys T.H. , Nguyen Trang , Oliver Edwina May , Matti Juliana , Alexiadis Maria , Silke John , Jobling Thomas W. , Fuller Peter J. , Chu Simon
Published: April 2023

Figure S4. Effects of combined PPARg activation and XIAP inhibition in GCT explant.
Supplementary Figure S1 from Chromatin Regulators as a Guide for Cancer Treatment Choice
Authors: Gurard-Levin Zachary A. , Wilson Laurence O.W. , Pancaldi Vera , Postel-Vinay Sophie , Sousa Fabricio G. , Reyes Cecile , Marangoni Elisabetta , Gentien David , Valencia Alfonso , Pommier Yves , Cottu Paul , Almouzni Geneviève
Published: April 2023

Chromatin regulators included in this study
Supplementary Figure Legends from Chromatin Regulators as a Guide for Cancer Treatment Choice
Authors: Gurard-Levin Zachary A. , Wilson Laurence O.W. , Pancaldi Vera , Postel-Vinay Sophie , Sousa Fabricio G. , Reyes Cecile , Marangoni Elisabetta , Gentien David , Valencia Alfonso , Pommier Yves , Cottu Paul , Almouzni Geneviève
Published: April 2023

Figure legends for Supplementary Material
Supplementary Table S1 from An Artificially Designed Interfering lncRNA Expressed by Oncolytic Adenovirus Competitively Consumes OncomiRs to Exert Antitumor Efficacy in Hepatocellular Carcinoma
Authors: Li Xiaoya , Su Yinghan , Sun Bin , Ji Weidan , Peng Zhangxiao , Xu Yang , Wu Mengchao , Su Changqing
Published: April 2023

OncomiRs and their complementary binding sequence within lncRNAi
Conflict of Interest Form from An Artificially Designed Interfering lncRNA Expressed by Oncolytic Adenovirus Competitively Consumes OncomiRs to Exert Antitumor Efficacy in Hepatocellular Carcinoma
Authors: Li Xiaoya , Su Yinghan , Sun Bin , Ji Weidan , Peng Zhangxiao , Xu Yang , Wu Mengchao , Su Changqing
Published: April 2023

Conflict of Interest Form from An Artificially Designed Interfering lncRNA Expressed by Oncolytic Adenovirus Competitively Consumes OncomiRs to Exert Antitumor Efficacy in Hepatocellular Carcinoma
Supplementary materials and methods. Supplementary tables 1 -6. from The Potential Roles of Long Noncoding RNAs (lncRNA) in Glioblastoma Development
Authors: Liu Shuang , Mitra Ramkrishna , Zhao Ming-Ming , Fan Wenhong , Eischen Christine M. , Yin Feng , Zhao Zhongming
Published: April 2023

The supplementary data include the detailed description about our GBM patient samples in house and the Cancer Genome Atlas GBM patient samples.The tables about informations of 20 in house GBM patients and the summaries of bioinformation analysis of our microArray results were also included. Table S1:The primer information of selected lncRNAs and genes for real-time RT-PCR detection Table S2: Summary of the In-house GBM samples Table S3: Summary of co-expression relationship among aberrantly expressed lncRNAs and genes in GBM Table S4: Over-represented pathways in the aberrantly expressed lncRNA-gene co-expression network Table S5: Over-represented Gene Ontology biological process terms in the aberrantly expressed lncRNA-gene co-expression network Table S6: GBM specific pathways and GO biological process (BP) terms link to genes selected for qRT-PCR analysis
Supplementary Figure 6 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
Authors: Onion David , Argent Richard H. , Reece-Smith Alexander M. , Craze Madeleine L. , Pineda Robert G. , Clarke Philip A. , Ratan Hari L. , Parsons Simon L. , Lobo Dileep N. , Duffy John P. , Atherton John C. , McKenzie Andrew J. , Kumari Rajendra , King Peter , Hall Brett M. , Grabowska Anna M.
Published: April 2023

Drug sensitivity of NSCLC specimens to standard of care reagents.
Supplementary Methods from Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer
Authors: Kozyreva Varvara K. , Kiseleva Anna A. , Ice Ryan J. , Jones Brandon C. , Loskutov Yuriy V. , Matalkah Fatimah , Smolkin Matthew B. , Marinak Kristina , Livengood Ryan H. , Salkeni Mohamad A. , Wen Sijin , Hazard Hannah W. , Layne Ginger P. , Walsh Callee M. , Cantrell Pamela S. , Kilby Greg W. , Mahavadi Sricharan , Shah Neal , Pugacheva Elena N.
Published: April 2023

File contains detailed protocols and information on used reagents to facilitate reproducible of the presented data.
Figure S5. Trametinib Overcomes Dasatinib Resistance in a Flank model of thyroid tumorigenesis. from The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer
Authors: Beadnell Thomas C. , Mishall Katie M. , Zhou Qiong , Riffert Stephen M. , Wuensch Kelsey E. , Kessler Brittelle E. , Corpuz Maia L. , Jing Xia , Kim Jihye , Wang Guoliang , Tan Aik Choon , Schweppe Rebecca E.
Published: April 2023

Tumor weights were measured upon euthanasia for both the Cal62 DasRes and Parental cell lines treated for 29 days with 1mg/kg QD trametinib. Data as means +/- SEM (n=8; student t-test; ***, P < 0.0005)
Supplementary Figure 1 Supplementary Table 1 from Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy
Authors: Kim Jeffrey , Ulu Arzu , Wan Debin , Yang Jun , Hammock Bruce D , Weiss Robert H.
Published: April 2023

Supplementary Figure S1. Tumor volumes in mice normalized to day 0; Supplementary Table S1. Macronutrient compositions of diets used in mouse study.
Supplementary Figure 1 from Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma
Authors: Ang Joo Ern , Pal Akos , Asad Yasmin J. , Henley Alan T. , Valenti Melanie , Box Gary , de haven Brandon Alexis , Revell Victoria L. , Skene Debra J. , Venturi Miro , Rueger Ruediger , Meresse Valerie , Eccles Suzanne A. , de Bono Johann S. , Kaye Stanley B. , Workman Paul , Banerji Udai , Raynaud Florence I.
Published: April 2023

Applied MEK signature to the PI3K treated patient cohort Heat map illustrating the changes relative to baseline treatment in 21 metabolites (MEK signature) in Pictilisib Phase I cohort. Dose range 45 - 450 mg.
Supporting Information from Dual Carfilzomib and Doxorubicin–Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma
Authors: Ashley Jonathan D. , Quinlan Charissa J. , Schroeder Valerie A. , Suckow Mark A. , Pizzuti Vincenzo J. , Kiziltepe Tanyel , Bilgicer Basar
Published: April 2023

Supplementary Table S1. Zeta Potential of the Different Nanoparticles; Supplementary Figure S1. Drug loading efficiencies of Carfilzomib and Dox-Lipid
Figure S1 from Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
Authors: Roth Gaël S. , Macek Jilkova Zuzana , Zeybek Kuyucu Ayca , Kurma Keerthi , Ahmad Pour Séyédéh Tayébéh , Abbadessa Giovanni , Yu Yi , Busser Benoit , Marche Patrice N. , Leroy Vincent , Decaens Thomas
Published: April 2023

Apoptosis
Supplementary Table S1 from Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors
Authors: Uitdehaag Joost C.M. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Willemsen-Seegers Nicole , de Vetter Judith R.F. , Dylus Jelle , van Doornmalen Antoon M. , Kooijman Jeffrey , Sawa Masaaki , van Gerwen Suzanne J.C. , de Man Jos , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Compounds tested in study, overview of cell lines, cancer genes present in cell lines
Supplemental Figure S2 from MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma
Authors: Wu Shaofang , Wang Shuzhen , Zheng Siyuan , Verhaak Roel , Koul Dimpy , Yung W.K. Alfred
Published: April 2023

PI3K/mTOR inhibition induced MSK1 mRNA expression
Supplementary Table S1 and Supplementary Figures S1 from ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis
Authors: Subhash Vinod Vijay , Tan Shi Hui , Yeo Mei Shi , Yan Fui Leng , Peethala Praveen C. , Liem Natalia , Krishnan Vaidehi , Yong Wei Peng
Published: April 2023

Table S1. Primers used to amplify ATM gene; Figure S1. siRNA knock down of ATM in HGC 27 cells.
Table S2 from CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma
Authors: Däbritz J. Henry M. , Yu Yong , Milanovic Maja , Schönlein Martin , Rosenfeldt Mathias T. , Dörr Jan R. , Kaufmann Andreas M. , Dörken Bernd , Schmitt Clemens A.
Published: April 2023

Table S2 lists the genes comprising the gene set "senescence-related genes".
Table S1 from CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma
Authors: Däbritz J. Henry M. , Yu Yong , Milanovic Maja , Schönlein Martin , Rosenfeldt Mathias T. , Dörr Jan R. , Kaufmann Andreas M. , Dörken Bernd , Schmitt Clemens A.
Published: April 2023

Table S1 contains quantifications of BrdU/PI analyses depicted in main Figures 1 and 2.
Supplemental figure and table legends from CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma
Authors: Däbritz J. Henry M. , Yu Yong , Milanovic Maja , Schönlein Martin , Rosenfeldt Mathias T. , Dörr Jan R. , Kaufmann Andreas M. , Dörken Bernd , Schmitt Clemens A.
Published: April 2023

This file contains legends for supplemental figures 1-3 and for supplemental tables 1 and 2.
Supplementary figure 3 from EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB
Authors: Civenni Gianluca , Longoni Nicole , Costales Paula , Dallavalle Cecilia , García Inclán Cristina , Albino Domenico , Nuñez Luz Elena , Morís Francisco , Carbone Giuseppina M. , Catapano Carlo V.
Published: April 2023

Supplementary figure 3. Cell viability evaluated by SRB assay after treatment with EC-70124 in PC3
Table S1-4 from MiR-125b Increases Nasopharyngeal Carcinoma Radioresistance by Targeting A20/NF-κB Signaling Pathway
Authors: Li Li-Na , Xiao Ta , Yi Hong-Mei , Zheng Zhen , Qu Jia-Quan , Huang Wei , Ye Xu , Yi Hong , Lu Shan-Shan , Li Xin-Hui , Xiao Zhi-Qiang
Published: April 2023

Supplementary Table S1. The clinicopathological parameters of 111 patients with nasopharygeal carcinoma; Supplementary Table S2. QRT-PCR primers for amplification of miR-125b and A20 synthesized by Ribobio; Supplementary Table 3. The levels of A20 and p-p65 (RelA) in the normal nasopharyngeal mucosa and nasopharygeal carcinoma tissues; Supplementary Table S4. Univariate and multivariate analyses of prognostic factors for overall and disease-free survival using Cox proportional hazards regression model (N =111)
Figure S5 from JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
Authors: Shien Kazuhiko , Papadimitrakopoulou Vassiliki A. , Ruder Dennis , Behrens Carmen , Shen Li , Kalhor Neda , Song Juhee , Lee J. Jack , Wang Jing , Tang Ximing , Herbst Roy S. , Toyooka Shinichi , Girard Luc , Minna John D. , Kurie Jonathan M. , Wistuba Ignacio I. , Izzo Julie G.
Published: April 2023

Figure S5. The effect of rhOSM on cell viability. Three NSCLC cell lines were treated by rhOSM (10 ng/ml) for 1week and then cell viability were measured by MTT assay.
Figure S3 from JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
Authors: Shien Kazuhiko , Papadimitrakopoulou Vassiliki A. , Ruder Dennis , Behrens Carmen , Shen Li , Kalhor Neda , Song Juhee , Lee J. Jack , Wang Jing , Tang Ximing , Herbst Roy S. , Toyooka Shinichi , Girard Luc , Minna John D. , Kurie Jonathan M. , Wistuba Ignacio I. , Izzo Julie G.
Published: April 2023

Figure S3. Activated pathway analysis after proinflammatory cytokine stimulation in NSCLC cells. H23 cells were transfected with an siRNA specific for IL6 cytokine receptors (OSMR, LIFR), JAK family members, or scrambled negative control for 72 hours and then were treated with an IL6 family-cytokine (rhIL6, rhOSM, rhLIF; 1 ng.mL) for 1 hour. Expression levels of indicated proteins in cell lysates were analyzed by Western blotting. Sufficient knockdown efficacy by each siRNA was confirmed. When JAK1 was knocked down, expression of OSMR was also downregulated.
Supplemental Figures 1-6 from Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer
Authors: Jabbour-Leung Natalie A. , Chen Xian , Bui Tuyen , Jiang Yufeng , Yang Dong , Vijayaraghavan Smruthi , McArthur Mark J. , Hunt Kelly K. , Keyomarsi Khandan
Published: April 2023

Six supplemental Figures are included in this file. The figure titles are as follows: Supplemental Figure 1. Changes in G2/M cell cycle phase following treatment as a function of receptor status. Supplemental Figure 2. Downreguation of CDK1, CDK2 or both in ER positive cells. Supplemental Figure 3. Cell cycle analysis following single or combination treatments. Supplemental Figure 4. Sequential combination treatment of roscovitine and doxorubicin causes more DNA double strand breaks in p53 mutant in colon cancer cells. . Supplemental Figure 5. Sequential roscovitine-doxorubicin combination treatment is effective and well tolerated in vivo. Supplemental Figure 6 Dose escalation of doxorubicin in vivo
Figure S4 from Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
Authors: Alcaraz-Sanabria Ana , Nieto-Jiménez Cristina , Corrales-Sánchez Verónica , Serrano-Oviedo Leticia , Andrés-Pretel Fernando , Montero Juan Carlos , Burgos Miguel , Llopis Juan , Galán-Moya Eva María , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

Fluorescence imaging of aberrant mitotic formation and caspase-3 activity in response to Alisertib and LY2603618 in ovarian cell lines
Figure S3 from Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer
Authors: Alcaraz-Sanabria Ana , Nieto-Jiménez Cristina , Corrales-Sánchez Verónica , Serrano-Oviedo Leticia , Andrés-Pretel Fernando , Montero Juan Carlos , Burgos Miguel , Llopis Juan , Galán-Moya Eva María , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

Combination of Alisertib and LY2603618 induced G2/M arrest in SKOV3.
Supplementary. Fig. S7 from Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44
Authors: Yi Jun-Mei , Huan Xia-Juan , Song Shan-Shan , Zhou Hu , Wang Ying-Qing , Miao Ze-Hong
Published: April 2023

BRCA1 or WWP2 does not mediate Rpb1 degradation induced by triptolide
Table S1 from Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2
Authors: Weiswald Louis-Bastien , Hasan Mohammad R. , Wong John C.T. , Pasiliao Clarissa C. , Rahman Mahbuba , Ren Jianhua , Yin Yaling , Gusscott Samuel , Vacher Sophie , Weng Andrew P. , Kennecke Hagen F. , Bièche Ivan , Schaeffer David F. , Yapp Donald T. , Tai Isabella T.
Published: April 2023

CDK10 expression in CRC based on a meta-analysis of independent gene expression profiling studies [7].
Supplementary Figure Legends from Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2
Authors: Weiswald Louis-Bastien , Hasan Mohammad R. , Wong John C.T. , Pasiliao Clarissa C. , Rahman Mahbuba , Ren Jianhua , Yin Yaling , Gusscott Samuel , Vacher Sophie , Weng Andrew P. , Kennecke Hagen F. , Bièche Ivan , Schaeffer David F. , Yapp Donald T. , Tai Isabella T.
Published: April 2023

Legends of Figures S1-S6
Figure S2 from Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2
Authors: Weiswald Louis-Bastien , Hasan Mohammad R. , Wong John C.T. , Pasiliao Clarissa C. , Rahman Mahbuba , Ren Jianhua , Yin Yaling , Gusscott Samuel , Vacher Sophie , Weng Andrew P. , Kennecke Hagen F. , Bièche Ivan , Schaeffer David F. , Yapp Donald T. , Tai Isabella T.
Published: April 2023

Densitometry analysis of western blot shown in Figure 2F (*p<0.05, **p<0.01, ***p<0.001).
Supplementary Table from Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression
Authors: Shi Liang , Lin Hui , Li Gonghui , Jin Ren-An , Xu Junjie , Sun Yin , Ma Wen-Lung , Yeh Shuyuan , Cai Xiujun , Chang Chawnshang
Published: April 2023

primer sequence used in this manuscript
Supplemental Figure 6 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
Authors: Sinik Lenka , Minson Katherine A. , Tentler John J. , Carrico Jacqueline , Bagby Stacey M. , Robinson William A. , Kami Rotem , Burstyn-Cohen Tal , Eckhardt S. Gail , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , DeRyckere Deborah , Graham Douglas K.
Published: April 2023

Supplemental Figures 6 shows efficacy of UNC2025 in a melanoma wild-type PDX mode.
Supplemental Figure 5 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
Authors: Sinik Lenka , Minson Katherine A. , Tentler John J. , Carrico Jacqueline , Bagby Stacey M. , Robinson William A. , Kami Rotem , Burstyn-Cohen Tal , Eckhardt S. Gail , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , DeRyckere Deborah , Graham Douglas K.
Published: April 2023

Supplemental Figure 5 shows impact of UNC2025 on cell death.
Supplemental Figure 2 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
Authors: Sinik Lenka , Minson Katherine A. , Tentler John J. , Carrico Jacqueline , Bagby Stacey M. , Robinson William A. , Kami Rotem , Burstyn-Cohen Tal , Eckhardt S. Gail , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , DeRyckere Deborah , Graham Douglas K.
Published: April 2023

Supplemental Figure 2 shows impact of UNC2025 on colony forming potential.
Supplemental Figure 1 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
Authors: Sinik Lenka , Minson Katherine A. , Tentler John J. , Carrico Jacqueline , Bagby Stacey M. , Robinson William A. , Kami Rotem , Burstyn-Cohen Tal , Eckhardt S. Gail , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , DeRyckere Deborah , Graham Douglas K.
Published: April 2023

Supplemental Figure 1 shows inhibition of downstream signaling under normal growth conditions.
Supplemental Figure 3 from Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer
Authors: Railkar Reema , Krane L. Spencer , Li Q. Quentin , Sanford Thomas , Siddiqui Mohammad Rashid , Haines Diana , Vourganti Srinivas , Brancato Sam J. , Choyke Peter L. , Kobayashi Hisataka , Agarwal Piyush K.
Published: April 2023

Cytotoxic dose of NIR for individual cell lines
Supplementary information from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
Authors: Clémenson Céline , Chargari Cyrus , Liu Winchygn , Mondini Michele , Ferté Charles , Burbridge Mike F. , Cattan Valérie , Jacquet-Bescond Anne , Deutsch Eric
Published: April 2023

Supplementary materials and methods and supplementary Figure and Table legends
Supplementary Table S1 from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
Authors: Clémenson Céline , Chargari Cyrus , Liu Winchygn , Mondini Michele , Ferté Charles , Burbridge Mike F. , Cattan Valérie , Jacquet-Bescond Anne , Deutsch Eric
Published: April 2023

Tumor growth delays of subcutaneous tumors
Supplementary Figure S6 from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
Authors: Clémenson Céline , Chargari Cyrus , Liu Winchygn , Mondini Michele , Ferté Charles , Burbridge Mike F. , Cattan Valérie , Jacquet-Bescond Anne , Deutsch Eric
Published: April 2023

Late effect of S49076 treatment
Supplementary Figure S5 from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
Authors: Clémenson Céline , Chargari Cyrus , Liu Winchygn , Mondini Michele , Ferté Charles , Burbridge Mike F. , Cattan Valérie , Jacquet-Bescond Anne , Deutsch Eric
Published: April 2023

In vivo activity of S49076 and ionizing radiation combination
Supplementary Figure S4 from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
Authors: Clémenson Céline , Chargari Cyrus , Liu Winchygn , Mondini Michele , Ferté Charles , Burbridge Mike F. , Cattan Valérie , Jacquet-Bescond Anne , Deutsch Eric
Published: April 2023

S49076 tumor concentration
Supplemental Materials and Methods from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines
Authors: Kani Kian , Garri Carolina , Tiemann Katrin , Malihi Paymaneh D. , Punj Vasu , Nguyen Anthony L. , Lee Janet , Hughes Lindsey D. , Alvarez Ruth M. , Wood Damien M. , Joo Ah Young , Katz Jonathan E. , Agus David B. , Mallick Parag
Published: April 2023

Supplemental text, figures, and data
Supplementary Figure S1 from The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy
Authors: Clémenson Céline , Chargari Cyrus , Liu Winchygn , Mondini Michele , Ferté Charles , Burbridge Mike F. , Cattan Valérie , Jacquet-Bescond Anne , Deutsch Eric
Published: April 2023

S49076 in vitro activity
Table S3 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Authors: Puskás László G. , Mán Imola , Szebeni Gabor , Tiszlavicz László , Tsai Susan , James Michael A.
Published: April 2023

In vitro characterization of monoclonal anti-CLPTM1L antibodies
Table S2 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Authors: Puskás László G. , Mán Imola , Szebeni Gabor , Tiszlavicz László , Tsai Susan , James Michael A.
Published: April 2023

Selected epitopes for monoclonal antibody development
Supplemetary Tables from Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation
Authors: Samadder Pounami , Suchánková Tereza , Hylse Ondřej , Khirsariya Prashant , Nikulenkov Fedor , Drápela Stanislav , Straková Nicol , Vaňhara Petr , Vašíčková Kateřina , Kolářová Hana , Binó Lucia , Bittová Miroslava , Ovesná Petra , Kollár Peter , Fedr Radek , Ešner Milan , Jaroš Josef , Hampl Aleš , Krejčí Lumír , Paruch Kamil , Souček Karel
Published: April 2023

Table S1. Mouse plasma protein binding profile of MU380 and SCH900776. Table S2. IC50 determination of main P450 cytochrome isoforms in human liver microsomes. Table S3. A) Evaluation of MU380 and SCH900776 disappearance with time in the presence of human liver microsomes. B) Human microsomal stability intrinsic clearance data for MU380 and SCH900776. Table S4. Statistical analysis of dose response curves for cell lines indicated in the Figure 3A. Table S5. Statistical analysis of dose response curves for cell lines indicated in the Figure 3B. Table S6. Distribution properties of SCH900776 and MU380 obtained using Caco-2 permeability drug assay. Table S7. Pharmacokinetics of SCH900776 and MU380. Table S8. Residual kinase activities for SCH900776, MU380, and MU378 (1â€‰Î¼mol/L) measured in a panel of 207 human kinases (Eurofins KinaseProfiler service). Table S9. The median survival time. Table S10. Log-rank (Mantel-Cox) test, used to assess the statistical differences in survival curves among the groups. Table S11. Available data for mutational status of the cell lines included in the screen were extracted from Cancer Cell Line Encyclopedia (CCLE) database.
Supplementary figure legends from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Authors: Puskás László G. , Mán Imola , Szebeni Gabor , Tiszlavicz László , Tsai Susan , James Michael A.
Published: April 2023

Supplementary figure legends
Supplementary Methods from Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation
Authors: Samadder Pounami , Suchánková Tereza , Hylse Ondřej , Khirsariya Prashant , Nikulenkov Fedor , Drápela Stanislav , Straková Nicol , Vaňhara Petr , Vašíčková Kateřina , Kolářová Hana , Binó Lucia , Bittová Miroslava , Ovesná Petra , Kollár Peter , Fedr Radek , Ešner Milan , Jaroš Josef , Hampl Aleš , Krejčí Lumír , Paruch Kamil , Souček Karel
Published: April 2023

Detail description of Material and Methods
Table S2 from Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor
Authors: Zeng Shan , Seifert Adrian M. , Zhang Jennifer Q. , Cavnar Michael J. , Kim Teresa S. , Balachandran Vinod P. , Santamaria-Barria Juan A. , Cohen Noah A. , Beckman Michael J. , Medina Benjamin D. , Rossi Ferdinand , Crawley Megan H. , Loo Jennifer K. , Maltbaek Joanna H. , Besmer Peter , Antonescu Cristina R. , DeMatteo Ronald P.
Published: April 2023

Supplementary Table 2: Primary untreated (Prim/UT) KIT+ ( n = 8 ) vs. Metastatic resistant (Met/Res) KIT+ ( n = 4). Significant genes with a False Discovery Rate of < 0.05 and a fold change > 2.0
supplementary figure S1 from The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks
Authors: Bombarde Oriane , Larminat Florence , Gomez Dennis , Frit Philippe , Racca Carine , Gomes Bruno , Guilbaud Nicolas , Calsou Patrick
Published: April 2023

Figure S1 shows the influence of drug removal on the extent of DSB production in cells.
supplementary Figure S5 from The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks
Authors: Bombarde Oriane , Larminat Florence , Gomez Dennis , Frit Philippe , Racca Carine , Gomes Bruno , Guilbaud Nicolas , Calsou Patrick
Published: April 2023

FIG. S5 Shows the role for CtIP-dependent DNA repair in survival of U2OS, HeLa and HT1080 cells to etoposide and F14512.
supplementary Figure S3 from The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks
Authors: Bombarde Oriane , Larminat Florence , Gomez Dennis , Frit Philippe , Racca Carine , Gomes Bruno , Guilbaud Nicolas , Calsou Patrick
Published: April 2023

Figure S3 shows the monitoring of the levels of TOP2α cleavage complexes in cells by the ICE bioassay.
Figure S3 from Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor
Authors: Zeng Shan , Seifert Adrian M. , Zhang Jennifer Q. , Cavnar Michael J. , Kim Teresa S. , Balachandran Vinod P. , Santamaria-Barria Juan A. , Cohen Noah A. , Beckman Michael J. , Medina Benjamin D. , Rossi Ferdinand , Crawley Megan H. , Loo Jennifer K. , Maltbaek Joanna H. , Besmer Peter , Antonescu Cristina R. , DeMatteo Ronald P.
Published: April 2023

Supplementary Figure 3: the interaction between endogenous Î²-catenin and COP1 in human GIST specimens.
Supplementary Table S1 from Dissecting Therapeutic Resistance to ERK Inhibition
Authors: Jha Sharda , Morris Erick J. , Hruza Alan , Mansueto My Sam , Schroeder Gottfried K. , Arbanas Jaren , McMasters Daniel , Restaino Clifford R. , Dayananth Priya , Black Stuart , Elsen Nathaniel L. , Mannarino Anthony , Cooper Alan , Fawell Stephen , Zawel Leigh , Jayaraman Lata , Samatar Ahmed A.
Published: April 2023

HTRF and Biacore binding data for active and inactive ERK1 in the presence of SCH772984
Supplementary Table 5 from Dual Inhibition of NOX2 and Receptor Tyrosine Kinase by BJ-1301 Enhances Anticancer Therapy Efficacy via Suppression of Autocrine-Stimulatory Factors in Lung Cancer
Authors: Gautam Jaya , Ku Jin-Mo , Regmi Sushil Chandra , Jeong Hyunyoung , Wang Ying , Banskota Suhrid , Park Myo-Hyeon , Nam Tae-gyu , Jeong Byeong-Seon , Kim Jung-Ae
Published: April 2023

The Absolute mRNA expression (Ct andã…¿Ct values*) of NOX isoforms and regulatory subunits in A549 and H1299 cells
Supplementary Information Figure S4 from Dissecting Therapeutic Resistance to ERK Inhibition
Authors: Jha Sharda , Morris Erick J. , Hruza Alan , Mansueto My Sam , Schroeder Gottfried K. , Arbanas Jaren , McMasters Daniel , Restaino Clifford R. , Dayananth Priya , Black Stuart , Elsen Nathaniel L. , Mannarino Anthony , Cooper Alan , Fawell Stephen , Zawel Leigh , Jayaraman Lata , Samatar Ahmed A.
Published: April 2023

Analysis of active ERK1 G186D mutant binding to SCH772984
Supplementary Table1 from BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer
Authors: Wu Xinchao , Liu Dong , Tao Dan , Xiang Wei , Xiao Xingyuan , Wang Miao , Wang Liang , Luo Gang , Li Yawei , Zeng Fuqing , Jiang Guosong
Published: April 2023

BRD4, C-MYC and EZH2 ShRNAs target sequences
Figure S2 from Herpes Simplex Virus Glycoprotein D Targets a Specific Dendritic Cell Subset and Improves the Performance of Vaccines to Human Papillomavirus-Associated Tumors
Authors: Porchia Bruna F.M.M. , Moreno Ana Carolina R. , Ramos Rodrigo N. , Diniz Mariana O. , de Andrade Laís Helena T.M. , Rosa Daniela S. , Barbuto José Alexandre M. , Boscardin Silvia B. , Ferreira Luís Carlos S.
Published: April 2023

Figure S2. Polymixin B inhibits LPS-induced up-regulation of co-stimulatory molecules and secretion of inflammatory cytokines in both mouse and human DCs.
Supplementary Table 1 from MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Authors: Li Peilong , Zhang Xin , Wang Haiyan , Wang Lili , Liu Tong , Du Lutao , Yang Yongmei , Wang Chuanxin
Published: April 2023

Supplementary Table 1 Information of the RT-qPCR primer sequence and siRNA sequence
Supplemental Table 1 from Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption
Authors: Xu Leqin , Luo Jian , Jin Rongrong , Yue Zhiying , Sun Peng , Yang Zhengfeng , Yang Xinghai , Wan Wei , Zhang Jishen , Li Shichang , Liu Mingyao , Xiao Jianru
Published: April 2023

Epidemiological, clinical, and pathological characteristics of 52 GCTB patients
Supplementary Figure 3 from MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Authors: Li Peilong , Zhang Xin , Wang Haiyan , Wang Lili , Liu Tong , Du Lutao , Yang Yongmei , Wang Chuanxin
Published: April 2023

Supplementary Figure 3. Validation of RNA immunoprecipitation by western blot with EZH2 antibody
Supplementary Figure 1 from MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
Authors: Li Peilong , Zhang Xin , Wang Haiyan , Wang Lili , Liu Tong , Du Lutao , Yang Yongmei , Wang Chuanxin
Published: April 2023

Supplementary Figure 1. The cut-off value of MALAT1 was established by using receiver operating characteristic (ROC) analysis in 53 serum samples from metastatic CRC patients treated with oxaliplatin, to distinguish the responding and non-responding patients receiving oxaliplatin-based treatment.
Supplementary Figure S6 from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
Authors: Langdon Casey G. , Platt James T. , Means Robert E. , Iyidogan Pinar , Mamillapalli Ramanaiah , Klein Michael , Held Matthew A. , Lee Jong Woo , Koo Ja Seok , Hatzis Christos , Hochster Howard S. , Stern David F.
Published: April 2023

Pairwise similarities of Yale, GDSC and CCLE datasets
Supplementary Figure S1 from Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide–Generating Agents Improves the Therapeutic Effects of Nanomedicines
Authors: Islam Waliul , Fang Jun , Imamura Takahisa , Etrych Tomas , Subr Vladimir , Ulbrich Karel , Maeda Hiroshi
Published: April 2023

Supplementary Figure S1 shows increased fluorescence image of S180 tumor treated with of HPMA-copolymer-conjugated zinc protoporphyrin (PZP) in combination with NO donors.
Supplementary materials from Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth
Authors: Tauro Marilena , Shay Gemma , Sansil Samer S. , Laghezza Antonio , Tortorella Paolo , Neuger Anthony M. , Soliman Hatem , Lynch Conor C.
Published: April 2023

Table S1. UV calibration line parameters for BMMPI quantification. Figure S1. MMP-2 expression in murine and human breast cancer cell lines and BMMPI structure. Figure S2. Selective MMP-2 inhibition by the BMMPIs ML104 and ML115. Figure S3. Impact of BMMPIs on 4T1 bone metastatic breast cancer growth and osteolysis. Figure S4. ML115 is rapidly cleared from the plasma and accumulates in the bone marrow microenvironment over time. effects.Figure S5. The addition of exogenous TGFβ protects breasts cancer cells from BMMPI
Supplementary Figure 2 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
Authors: Chen Luxi , Yuan Yi , Kar Shreya , Kanchi Madhu M. , Arora Suruchi , Kim Ji E. , Koh Pei F. , Yousef Einas , Samy Ramar P. , Shanmugam Muthu K. , Tan Tuan Z. , Shin Sung W. , Arfuso Frank , Shen Han M. , Yang Henry , Goh Boon C. , Park Joo I. , Gaboury Louis , Lobie Peter E. , Sethi Gautam , Lim Lina H.K. , Kumar Alan P.
Published: April 2023

Supplementary Figure 2: ANXA1 expressing TNBC cell lines display greater sensitivity to PPARγ ligands compared to ANXA1 depleted cells.
Supplemental Figure legends from Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy
Authors: Tyler Paul M. , Servos Mariah M. , de Vries Romy C. , Klebanov Boris , Kashyap Trinayan , Sacham Sharon , Landesman Yosef , Dougan Michael , Dougan Stephanie K.
Published: April 2023

Legends for supplemental figures
Figure S5 from Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice
Authors: Wang Rong , Yamada Tadaaki , Arai Sachiko , Fukuda Koji , Taniguchi Hirokazu , Tanimoto Azusa , Nishiyama Akihiro , Takeuchi Shinji , Yamashita Kaname , Ohtsubo Koshiro , Matsui Junji , Onoda Naoyoshi , Hirata Eishu , Taira Shu , Yano Seiji
Published: April 2023

Supplementary Figure 5 shows tandem MS spectra of lenvatinib and sorafenib.
Figure S1 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death
Authors: Asthana Abhishek , Ramakrishnan Parameswaran , Vicioso Yorleny , Zhang Keman , Parameswaran Reshmi
Published: April 2023

Comparative expression of genes involved in O-GlcNAcylation.
Table S3 from Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis
Authors: Huang Huang-Chiao , Liu Joyce , Baglo Yan , Rizvi Imran , Anbil Sriram , Pigula Michael , Hasan Tayyaba
Published: April 2023

Preliminary analysis of combining minocycline and irinotecan regimen indicates significant cost savings compared to other irinotecan-based combination therapies.
Table S3 from Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors
Authors: Marzi Laetitia , Agama Keli , Murai Junko , Difilippantonio Simone , James Amy , Peer Cody J. , Figg William D. , Beck Daniel , Elsayed Mohamed S.A. , Cushman Mark , Pommier Yves
Published: April 2023

Pharmacokinetic of LMP135, LMP134 and LMP517
Figure S6 from Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell–like Property and Metastasis in Breast Cancer
Authors: Hao Na , Shen Wenzhi , Du Renle , Jiang Shan , Zhu Junyong , Chen Yanan , Huang Chongbiao , Shi Yi , Xiang Rong , Luo Yunping
Published: April 2023

Figure S6 shows that the side effects of Cilostazol.
Figure S5 from Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell–like Property and Metastasis in Breast Cancer
Authors: Hao Na , Shen Wenzhi , Du Renle , Jiang Shan , Zhu Junyong , Chen Yanan , Huang Chongbiao , Shi Yi , Xiang Rong , Luo Yunping
Published: April 2023

Figure S5 shows that Cilostazol inhibits breast cancer stemness and metastasis.
Supplementary Figure 1A from Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin
Authors: Nagel Remco , Avelar Ana Teresa , Aben Nanne , Proost Natalie , van de Ven Marieke , van der Vliet Jan , Cozijnsen Miranda , de Vries Hilda , Wessels Lodewyk F. A. , Berns Anton
Published: April 2023

Supplementary figure 1A. Sequencing tracks of a part of the Zwilch gene targeted by a first unique sgRNA, with the wildtype sequence (top) and sgRNA treated sequence (bottom) shown. B. Tide analysis showing editing efficiency of the first Zwilch targeting sgRNA
Supplementary Table S1 from Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response
Authors: Pishas Kathleen I. , Drenberg Christina D. , Taslim Cenny , Theisen Emily R. , Johnson Kirsten M. , Saund Ranajeet S. , Pop Ioana L. , Crompton Brian D. , Lawlor Elizabeth R. , Tirode Franck , Mora Jaume , Delattre Olivier , Beckerle Mary C. , Callen David F. , Sharma Sunil , Lessnick Stephen L.
Published: April 2023

Cell line source/culture conditions, primer/shRNA sequences, antibodies utilized in this study and additional methods
Supplementary Figure 1 from Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response
Authors: Pishas Kathleen I. , Drenberg Christina D. , Taslim Cenny , Theisen Emily R. , Johnson Kirsten M. , Saund Ranajeet S. , Pop Ioana L. , Crompton Brian D. , Lawlor Elizabeth R. , Tirode Franck , Mora Jaume , Delattre Olivier , Beckerle Mary C. , Callen David F. , Sharma Sunil , Lessnick Stephen L.
Published: April 2023

Validation of KDM1A knockdown in Ewing sarcoma cells
Supplemental Figure 1-5 from Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma
Authors: Cheng Hanyin , Chua Vivian , Liao Connie , Purwin Timothy J. , Terai Mizue , Kageyama Ken , Davies Michael A. , Sato Takami , Aplin Andrew E.
Published: April 2023

Supplemental Figure 1: HGF inhibits trametinib-induced apoptosis in UM cells; Supplemental Figure 2: Bim-EL or Bmf expression renders UM cells susceptible to apoptosis; Supplemental Figure 3: Human hepatic stellate cell (HHSteC) conditioned medium activates HGF-cMET signaling; Supplemental Figure 4: Human hepatic stellate cell (HHSteC) conditioned medium effects on migration and invasion of UM cells; Supplemental Figure 5: Isoform specific PI3K inhibitors differentially block HGF-mediated activation of AKT in UM001 cells.
Supplementary Methods from Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy
Authors: Creevey Laura , Bleach Rachel , Madden Stephen F. , Toomey Sinead , Bane Fiona T. , Varešlija Damir , Hill Arnold D. , Young Leonie S. , McIlroy Marie
Published: April 2023

Supplemental methods
Supplementary Figure 1 from Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy
Authors: Creevey Laura , Bleach Rachel , Madden Stephen F. , Toomey Sinead , Bane Fiona T. , Varešlija Damir , Hill Arnold D. , Young Leonie S. , McIlroy Marie
Published: April 2023

AR ER protein densitometry and dose response to PI3K/mTORi
Supplementary Figure 1 from A Tricin Derivative from Deschampsia antarctica Desv. Inhibits Colorectal Carcinoma Growth and Liver Metastasis through the Induction of a Specific Immune Response
Authors: Malvicini Mariana , Gutierrez-Moraga Ana , Rodriguez Marcelo M. , Gomez-Bustillo Sofia , Salazar Lorena , Sunkel Carlos , Nozal Leonor , Salgado Antonio , Hidalgo Manuel , Lopez-Casas Pedro P. , Novella Jose Luis , Vaquero Juan Jose , Alvarez-Builla Julio , Mora Adda , Gidekel Manuel , Mazzolini Guillermo
Published: April 2023

In vivo efficacy of Tricin and 5-FU
Supplementary Table S5 from The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics
Authors: Martens-de Kemp Sanne R. , Brink Arjen , van der Meulen Ida H. , de Menezes Renée X. , te Beest Dennis E. , Leemans C. René , van Beusechem Victor W. , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Table S5. Characteristics of the patient groups extracted from Wichmann et al.(64) and used in Figure 4. Patients were selected on basis of a negative HPV test result as HPV will confound the prognostic associations. All patients were treated with multimodality therapy regimens with curative intent.
Supplementary Table S4 from The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics
Authors: Martens-de Kemp Sanne R. , Brink Arjen , van der Meulen Ida H. , de Menezes Renée X. , te Beest Dennis E. , Leemans C. René , van Beusechem Victor W. , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Table S4. Overview of selected probes that target the 102 genes found to sensitize HNSCC cells with two different statistical methods.
Supplementary Table S2 from The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics
Authors: Martens-de Kemp Sanne R. , Brink Arjen , van der Meulen Ida H. , de Menezes Renée X. , te Beest Dennis E. , Leemans C. René , van Beusechem Victor W. , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Table S2. List of siRNA SMARTpools that significantly sensitized VU-SCC-120 cells to cisplatin as identified by at least one of two separate statistical analyses.
Legends to supplementary figures from The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics
Authors: Martens-de Kemp Sanne R. , Brink Arjen , van der Meulen Ida H. , de Menezes Renée X. , te Beest Dennis E. , Leemans C. René , van Beusechem Victor W. , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

Legends to supplementary figures S1-S4
Supplementary Table S6 from In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance
Authors: Anisuzzaman Abu Syed Md , Haque Abedul , Wang Dongsheng , Rahman Mohammad Aminur , Zhang Chao , Chen Zhengjia , Chen Zhuo Georgia , Shin Dong M. , Amin A.R.M. Ruhul
Published: April 2023

Supplementary Table S6: Pair-wise p values for animal studies